Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions.

Trial Profile

Multi-center, Open-label, Uncontrolled Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Immunodeficiency disorders; Respiratory syncytial virus infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 14 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 14 May 2012 Actual patients number is 28 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top